Peptide Therapy in Longevity Medicine: What Is Proven, and What Is Sold

Peptide therapy uses short amino acid chains that act on one receptor or pathway. A small group, mainly the GLP-1 class, has randomised outcome evidence and regulatory approval. Most peptides marketed for longevity do not. Dr. Galani completed ISSCA Advanced Peptides Therapy certification on 28 July 2026.

Key points

• Peptides are short amino acid chains that signal to one specific receptor or pathway.
• Only a minority, chiefly metabolic peptides such as GLP-1 agonists, have approval and outcome trials.
• Unregulated peptides bought online are frequently mislabelled and are not monitored safely.
• minus10med considers peptides only after the Longevity Panel establishes a baseline.
• Dr. Galani holds ISSCA Advanced Peptides Therapy certification, issued 28 July 2026.

Certification changes the conversation from what is sold to what is known.

Peptides are short chains of amino acids that act as biological messengers. Some are already routine medicine, for example GLP-1 receptor agonists for metabolic disease. Others are still experimental, sold online, and used far ahead of the evidence. Advanced certification exists precisely because that gap is where patients get hurt.

What is peptide therapy, in plain terms?

A peptide is smaller than a protein and usually more specific in what it does. Therapeutic peptides are designed to bind one receptor or one pathway: appetite and insulin signalling, growth hormone release, tissue repair, immune modulation. That specificity is the appeal. It is also the reason a peptide can be inert in one clinical context and inappropriate in another.

In a longevity practice the honest split is three ways. Approved peptides with regulatory authorisation and outcome data. Peptides with credible mechanistic and early human data but no approval for the indication being discussed. And peptides with nothing behind them but marketing. Only the first group belongs in routine care.

Which peptides actually have evidence behind them?

The strongest evidence sits with the metabolic peptides. GLP-1 and dual GLP-1/GIP agonists have large randomised trials for weight and glycaemic outcomes, and the cardiology guideline bodies now reference them. Insulin, teriparatide for osteoporosis and several hormone analogues are similarly well characterised.

Growth hormone secretagogues, repair peptides such as BPC-157, and most of the "anti-aging" peptide catalogue sit in a different category. Animal data and small uncontrolled series are not the same as evidence of benefit, and purity of unregulated product is a real problem: independent testing repeatedly finds mislabelled content in compounds bought online.

Why did I take the ISSCA advanced certification?

I completed the Online Advanced Peptides Therapy Certification with the International Society for Stem Cell Application on 28 July 2026. The programme covers clinical application frameworks, indication selection, dosing and monitoring, and the regulatory and safety boundaries of regenerative and longevity peptide use.

The reason is simple. Patients arrive at the clinic already taking peptides they bought abroad or online, and they deserve a physician who can read the actual pharmacology rather than repeat a supplier's claim. Formal training makes the conversation specific: what this compound does, what is known, what is not, and what needs to be measured if you continue.

How does minus10med use peptides in a protocol?

Nothing is prescribed before the data exists. Peptides are considered only after the Longevity Panel has established metabolic, inflammatory, hormonal and cardiovascular baselines, and only where an approved compound matches a documented clinical problem. Where a patient is already self-administering something unapproved, the priority is monitoring and, often, a structured stop.

Every peptide-relevant plan is reviewed at the follow-up consultations built into each program, with repeat bloods rather than a subjective sense of progress. This mirrors how the rest of the regenerative work is run.

Should I start peptide therapy?

Not on the basis of an article, including this one. If you have a metabolic diagnosis, an approved peptide may be the correct treatment and should be prescribed and supervised by a physician. If you are healthy and curious, the value of measuring first and intervening second is far higher than any compound currently marketed for longevity.

If you are already using a peptide sourced outside a pharmacy, tell your physician. That single disclosure changes what your bloods mean.

Reviewed by Dr. Erietta Galani, MD, Internal Medicine and Intensive Care, evidence-informed longevity medicine, minus10med, Athens.
Last reviewed: 28 July 2026

This article is educational and does not replace individual medical advice, diagnosis or treatment.